4536 — SANTEN PHARMACEUTICAL Share News
0.000.00%
Last trade - 00:00- ¥558bn
- ¥537bn
- ¥292bn
Table: Santen Pharm -2021/22 group results (IFRS)
Table: Santen Pharm -9-MTH group results (IFRS)
Table: Santen Pharm -6-MTH group results (IFRS)
Table: Santen Pharm -Q1 group results (IFRS)
Table: Santen Pharm -2020/21 group results (IFRS)
Table: Santen Pharm -2020/21 parent results
Table: Santen Pharm -2020/21 group forecast(IFRS)
Table: Santen Pharm -9-MTH group results (IFRS)
Table: Santen Pharm -6-MTH group results (IFRS)
Brief: Santen Announces U.S. FDA Filing Acceptance Of New Drug Application (NDA) For Cyclosporine Topical Ophthalmic Emulsion, 0.1%
Table: Santen Pharm -Q1 group results (IFRS)
Brief: Santen Pharmaceutical - Announces U.S. FDA Acceptance Of Premarket Approval (Pma) Application For De-128 (Microshunt) For Review
Table: Santen Pharm -2019/20 parent results
Table: Santen Pharm -2019/20 group results (IFRS)
Table: Santen Pharm -9-MTH group results (IFRS)
Brief: Santen Receives INESSS Recommendation For Verkazia Eye Drops
Table: Santen Pharm -6-MTH group results (IFRS)
Brief: Santen Pharmaceutical Will Enter The Indian Market This Year - Nikkei
Table: Santen Pharm -Q1 group results (IFRS)